Most Read Articles
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

06 Feb 2017

The prevalence of benign prostate hypertrophy (BPH) increases with age and is more common in men aged 50 years and above. Dr Ronny Tan, consultant urologist and director of andrology at Tan Tock Seng Hospital, Singapore, speaks on how GPs can best manage this condition.

6 days ago
Long-term treatment with memantine is well tolerated but does not effectively prevent glaucomatous progression in patients with open-angle glaucoma (OAG), according to the results of two phase III trials.
Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.

Bisphosphonate ‘holiday’ tied to increased fracture risk

Roshini Claire Anthony
10 Nov 2017

Women who temporarily or permanently stop taking bisphosphonates (drug holiday) for an extended period of time may have an increased risk of hip fractures, findings from a recent population-based study revealed.

“[A] bisphosphonate drug holiday greater than 2 years was associated with a significantly increased risk for hip fracture of up to 39 percent compared with continued bisphosphonate use,” said study lead author Professor Jeffrey Curtis who presented the findings at the annual meeting of the ACR/ARHP* held in San Diego, California, US, on behalf of himself and his fellow investigators from the University of Alabama at Birmingham, Alabama, US.

Compared with current users (crude incidence rate, 9.6 per 1,000 person-years), women who had ceased bisphosphonate therapy for more than 2 and up to 3 years had the highest rate of fracture incidence (crude incidence rate, 15.7 per 1,000 person-years; adjusted hazard ratio [adjHR], 1.39). [ACR/ARHP 2017, abstract 828]

Women who had ceased bisphosphonate therapy for >0 to ≤3 months, >3 months to ≤1 year, and >1 to ≤2 years also had an increased risk of hip fracture (adjHR, 1.29, 1.12, and 1.21, respectively; crude incidence rate, 13.1, 12.0, and 13.3 per 1,000 person-years, respectively).

Using Medicare data from 2006 to 2014, researchers identified 156,236 women (mean age, 78.5 years) who were long-term users of bisphosphonate therapy and were ≥80 percent treatment-adherent for ≥3 years at baseline. Patients who used other bone therapies such as denosumab, oestrogen, calcitonin, or teriparatide were excluded.

Over a median 2.1-year follow-up period, 40.1 percent (n=62,676) of patients ceased bisphosphonate therapy for ≥6 months, 12.7 percent (n=7,947) of whom later restarted bisphosphonate therapy. There were 3,745 hip fractures reported during the follow-up period.

Hip fracture incidence was lowest among women currently on bisphosphonate therapy and increased with longer duration of drug holiday.

“Given FDA** warnings, drug holidays [temporary or permanent discontinuation] of bisphosphonates after long-term [3–5 years] continuous therapy is becoming increasingly common in the US,” said Curtis and colleagues.

“Our goal was to evaluate the risk of discontinuing therapy based on the length of the holiday, controlling for any possibly confounding factors, such as race, median income, rural or urban location, DXA scores, or comorbidities,” said Curtis.

“While the notion of a drug holiday has become commonplace in osteoporosis management, there’s a dearth of evidence on when we should consider restarting bisphosphonate therapy. The study’s findings may provide useful evidence to help guide rheumatologists as they plan long-term therapy for their patients dealing with low bone mass,” he added.  

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

06 Feb 2017

The prevalence of benign prostate hypertrophy (BPH) increases with age and is more common in men aged 50 years and above. Dr Ronny Tan, consultant urologist and director of andrology at Tan Tock Seng Hospital, Singapore, speaks on how GPs can best manage this condition.

6 days ago
Long-term treatment with memantine is well tolerated but does not effectively prevent glaucomatous progression in patients with open-angle glaucoma (OAG), according to the results of two phase III trials.
Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.